US20190336598A1 - Methods for modulating inflammasome activity and inflammation in the lung - Google Patents

Methods for modulating inflammasome activity and inflammation in the lung Download PDF

Info

Publication number
US20190336598A1
US20190336598A1 US16/474,708 US201716474708A US2019336598A1 US 20190336598 A1 US20190336598 A1 US 20190336598A1 US 201716474708 A US201716474708 A US 201716474708A US 2019336598 A1 US2019336598 A1 US 2019336598A1
Authority
US
United States
Prior art keywords
antibody
inflammasome
asc
aim2
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/474,708
Other languages
English (en)
Inventor
Robert W. Keane
W. Dalton Dietrich
Nadine KERR
Shu Wu
Juan Pablo De Rivero Vaccari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Priority to US16/474,708 priority Critical patent/US20190336598A1/en
Publication of US20190336598A1 publication Critical patent/US20190336598A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
Assigned to NATIONAL INSTITUTES OF HEALTH reassignment NATIONAL INSTITUTES OF HEALTH CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: MIAMI, UNIVERSITY OF
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • EV from TBI mice induced alveolar morphological changes (decreased alveolar size) and infiltration of inflammatory cells as determined by H&E staining ( FIG. 7G ).
  • ALI score is significantly increased in EV delivered from injured mice compared to uninjured mice ( FIG. 7H ).
  • binding fragments include: (i) an Fab fragment consisting of VL, VH, CL and CH1 domains (Ward, E. S. et al., (1989) Nature 341, 544-546); (ii) an Fd fragment consisting of the VH and CH1 domains (McCafferty et al., (1990) Nature, 348, 552-554); (iii) an Fv fragment consisting of the VL and VH domains of a single antibody (Holt et al., (2003) Trends in Biotechnology 21, 484-490); (iv) a dAb fragment (Ward, E. S.
  • NALP1 and NLRP1 mean an expression product of an NALP or NLRP1 gene or isoforms; or a protein that shares at least 65% (but preferably 75, 80, 85, 90, 95, 96, 97, 98, or 99%) amino acid sequence identity with NALP (e.g., accession number(s) AAH51787, NP_001028225, NP_127500, NP_127499, NP_127497, NP055737) and displays a functional activity of NALP1.
  • accession number(s) AAH51787, NP_001028225, NP_127500, NP_127499, NP_127497, NP055737 displays a functional activity of NALP1.
  • Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, GILD and any subclass thereof
  • a hybridoma producing a monoclonal antibody of the present invention may be cultivated in vitro, in situ or in vivo.
  • this Example showed that AIM2 inflammasome signaling plays a central role in the pathomechanism of lung injury after TBI and demonstrates a mechanism of TBI-induced ALI involving EV-mediated inflammasome signaling.
  • EV-mediated inflammasome signaling can play a central role involving a Neuronal-Respiratory-Inflammatory Axis. Therefore, targeting this axis with antibodies against inflammasome proteins or drugs that block EV uptake may provide a therapeutic approach in Neurotrauma-induced ALI in all areas of critical care medicine.
  • the disclosed therapeutic strategies may be useful for the treatment of inflammatory diseases of the lung in general.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US16/474,708 2016-12-29 2017-12-28 Methods for modulating inflammasome activity and inflammation in the lung Abandoned US20190336598A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/474,708 US20190336598A1 (en) 2016-12-29 2017-12-28 Methods for modulating inflammasome activity and inflammation in the lung

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662440180P 2016-12-29 2016-12-29
PCT/US2017/068713 WO2018126009A1 (en) 2016-12-29 2017-12-28 Method for modulating inflammasome activity and inflammation in the lung
US16/474,708 US20190336598A1 (en) 2016-12-29 2017-12-28 Methods for modulating inflammasome activity and inflammation in the lung

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/068713 A-371-Of-International WO2018126009A1 (en) 2016-12-29 2017-12-28 Method for modulating inflammasome activity and inflammation in the lung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/358,582 Continuation US20210324065A1 (en) 2016-12-29 2021-06-25 Methods for modulating inflammasome activity and inflammation in the lung

Publications (1)

Publication Number Publication Date
US20190336598A1 true US20190336598A1 (en) 2019-11-07

Family

ID=62710025

Family Applications (5)

Application Number Title Priority Date Filing Date
US16/474,708 Abandoned US20190336598A1 (en) 2016-12-29 2017-12-28 Methods for modulating inflammasome activity and inflammation in the lung
US16/026,482 Active US10703811B2 (en) 2016-12-29 2018-07-03 Methods and compositions for treating multiple sclerosis
US16/847,054 Active US10961306B2 (en) 2016-12-29 2020-04-13 Methods for treating lung inflammation with an anti-ASC antibody
US16/856,407 Active US11174307B2 (en) 2016-12-29 2020-04-23 Methods and compositions for treating virus-associated inflammation
US17/358,582 Abandoned US20210324065A1 (en) 2016-12-29 2021-06-25 Methods for modulating inflammasome activity and inflammation in the lung

Family Applications After (4)

Application Number Title Priority Date Filing Date
US16/026,482 Active US10703811B2 (en) 2016-12-29 2018-07-03 Methods and compositions for treating multiple sclerosis
US16/847,054 Active US10961306B2 (en) 2016-12-29 2020-04-13 Methods for treating lung inflammation with an anti-ASC antibody
US16/856,407 Active US11174307B2 (en) 2016-12-29 2020-04-23 Methods and compositions for treating virus-associated inflammation
US17/358,582 Abandoned US20210324065A1 (en) 2016-12-29 2021-06-25 Methods for modulating inflammasome activity and inflammation in the lung

Country Status (15)

Country Link
US (5) US20190336598A1 (de)
EP (2) EP3562506A4 (de)
JP (3) JP2020503345A (de)
KR (1) KR20200013630A (de)
CN (1) CN110461356A (de)
AU (1) AU2017386550A1 (de)
BR (1) BR112019013463A2 (de)
CA (2) CA3048864A1 (de)
CO (1) CO2019008087A2 (de)
IL (1) IL267685A (de)
MX (1) MX2019007916A (de)
PH (1) PH12019501549A1 (de)
RU (1) RU2019123160A (de)
SG (1) SG10202106385XA (de)
WO (2) WO2018126009A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703811B2 (en) 2016-12-29 2020-07-07 University Of Miami Methods and compositions for treating multiple sclerosis
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021222263A2 (en) * 2020-04-27 2021-11-04 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
CA3105129A1 (en) * 2018-07-03 2020-01-09 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
WO2021097084A1 (en) * 2019-11-12 2021-05-20 The Uab Research Foundation Methods for treating immunosuppression and diseases associated with immunosuppression
CN111363847B (zh) * 2020-02-12 2021-06-29 广州微远医疗器械有限公司 基于CRISPR技术的2019-nCoV快速检测引物组及其用途
CN113278730B (zh) * 2020-02-20 2022-03-25 中元汇吉生物技术股份有限公司 一种新型冠状病毒检测试剂盒、用途及其使用方法
WO2021188052A1 (en) * 2020-03-19 2021-09-23 Nanyang Technological University Use of a compound or composition comprising an inhibitor of nlrp1 inflammasome activation for the treatment of human airway inflammation
CN111289745A (zh) * 2020-03-25 2020-06-16 中山生物工程有限公司 新型冠状病毒IgM抗体酶联免疫检测试剂盒及其检测方法
KR102658146B1 (ko) * 2020-03-26 2024-04-18 경북대학교 산학협력단 Pannexin3을 포함하는 근육 손상 진단용 바이오마커 조성물 및 이를 이용한 진단방법
CN111529707B (zh) * 2020-04-29 2021-04-23 威海市立医院 Gsdmd抑制剂在制备治疗幽门螺杆菌感染的药物中的应用
CN111777684A (zh) * 2020-06-09 2020-10-16 重庆君同生物技术有限公司 冠状病毒串联表位蛋白所诱导抗体的制备方法及其应用
KR102582417B1 (ko) * 2020-11-06 2023-09-26 한국과학기술원 인플라마솜 어댑터 단백질(asc)의 중합체화 도메인에 결합하는 신규한 폴리펩타이드 및 이의 용도
CN113109569B (zh) * 2021-03-05 2022-08-19 李朴 Gsdmd作为生物标志物在胸腔积液相关疾病鉴别诊断及疗效评估上的用途
KR102673132B1 (ko) * 2021-04-20 2024-06-12 아주대학교산학협력단 염증성 질환 치료를 위한 nlrp3 인플라마좀 억제 펩타이드
EP4337676A1 (de) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Antigenbindende und antigenabbauende konstrukte
AU2022335541A1 (en) * 2021-08-25 2024-02-01 R.P. Scherer Technologies, Llc Antibodies having humanized framework regions
CN115819548B (zh) * 2021-11-16 2023-09-01 北京美德泰康生物科技有限公司 一种检测炎症相关疾病的标志物和方法
WO2024006457A1 (en) * 2022-06-29 2024-01-04 University Of South Florida Method of treating long-covid induced neurologic diseases
WO2024114906A1 (en) 2022-11-30 2024-06-06 Mabylon Ag Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
RU2407752C2 (ru) 2004-04-29 2010-12-27 Оцука Фармасьютикал Ко., Лтд. Антитела к гликопротеину vi и способы продуцирования и использования этих антител
US7780963B2 (en) 2004-10-25 2010-08-24 Merck & Co., Inc. Anti-ADDL antibodies and uses thereof
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
AU2008219666A1 (en) 2007-02-27 2008-09-04 Genentech, Inc. Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
WO2009014863A2 (en) * 2007-06-29 2009-01-29 Thomas Jefferson University Asc and pyrin-asc pyroptosomes and uses thereof
US8685400B2 (en) * 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
CA2729780A1 (en) * 2008-07-03 2010-01-07 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
KR20120080196A (ko) * 2009-09-11 2012-07-16 프로타핀 바이오테크놀로기 아게 Ｃｘｃｌ８-매개의 폐 염증을 치료하는 조성물
EP3195880B1 (de) 2010-05-14 2019-11-27 Amgen Inc. Hoch-konzentrierte anti-sclerostin antikörperformulierungen
IT1406201B1 (it) 2010-12-10 2014-02-14 Univ Degli Studi Trieste Biomarcatori per la diagnosi della sclerosi multipla
EP2684051B1 (de) 2011-03-11 2016-04-27 Roche Diagniostics GmbH Asc als marker für die chronisch obstruktive lungenerkrankung (copd)
WO2013119673A1 (en) 2012-02-06 2013-08-15 University Of Miami Innate immune proteins as biomarkers for cns injury
TWI480044B (zh) 2012-03-16 2015-04-11 Taichung Veterans General Hospital A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution
US20140314746A1 (en) * 2013-03-13 2014-10-23 Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine Methods for treating or preventing fibrosis in subjects afflicted with scleroderma
EP2997162A4 (de) * 2013-05-17 2017-02-01 F. Hoffmann-La Roche AG Verfahren zur diagnose und behandlung von entzündlicher darmerkrankung
WO2015016178A1 (ja) * 2013-07-29 2015-02-05 国立大学法人鹿児島大学 １，５－ｄ－アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬
AU2015204558B2 (en) * 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2016028699A2 (en) 2014-08-18 2016-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for diagnosis and management of neuro-immunological diseases
US20160263183A1 (en) 2015-03-10 2016-09-15 Brown University Methods for treating lung disease
CN114181281A (zh) * 2015-05-12 2022-03-15 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗
TWI743047B (zh) 2015-08-17 2021-10-21 安成生物科技股份有限公司 使用雙醋瑞因或其類似物抑制asc表現、nlrp3表現、以及/或nlrp3發炎體複合物的形成之方法
KR101948048B1 (ko) 2016-12-08 2019-02-14 한양대학교 에리카산학협력단 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물
SG10202106385XA (en) 2016-12-29 2021-07-29 Univ Miami Method for modulating inflammasome activity and inflammation in the lung
BR112020005445A2 (pt) 2017-09-20 2020-09-29 University Of Miami método para a detecção de proteínas do inflamassoma como biomarcadores de transtornos neurológicos
CA3105129A1 (en) 2018-07-03 2020-01-09 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703811B2 (en) 2016-12-29 2020-07-07 University Of Miami Methods and compositions for treating multiple sclerosis
US10961306B2 (en) 2016-12-29 2021-03-30 University Of Miami Methods for treating lung inflammation with an anti-ASC antibody
US11174307B2 (en) 2016-12-29 2021-11-16 University Of Miami Methods and compositions for treating virus-associated inflammation
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation

Also Published As

Publication number Publication date
US11174307B2 (en) 2021-11-16
CA3048864A1 (en) 2018-07-05
CN110461356A (zh) 2019-11-15
RU2019123160A3 (de) 2021-01-29
EP3562506A1 (de) 2019-11-06
BR112019013463A2 (pt) 2020-01-07
JP2023515271A (ja) 2023-04-12
JP2020503345A (ja) 2020-01-30
US10961306B2 (en) 2021-03-30
CO2019008087A2 (es) 2019-10-21
WO2021217004A2 (en) 2021-10-28
KR20200013630A (ko) 2020-02-07
CA3176518A1 (en) 2021-10-28
US20190002550A1 (en) 2019-01-03
SG10202106385XA (en) 2021-07-29
RU2019123160A (ru) 2021-01-29
EP4139348A2 (de) 2023-03-01
EP3562506A4 (de) 2021-01-06
US10703811B2 (en) 2020-07-07
JP2023016835A (ja) 2023-02-02
US20210324065A1 (en) 2021-10-21
MX2019007916A (es) 2019-12-05
WO2021217004A3 (en) 2021-12-16
US20200347124A1 (en) 2020-11-05
WO2018126009A1 (en) 2018-07-05
IL267685A (en) 2019-08-29
PH12019501549A1 (en) 2020-02-24
AU2017386550A1 (en) 2019-08-08
US20200308262A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
US20210324065A1 (en) Methods for modulating inflammasome activity and inflammation in the lung
US20210284723A1 (en) Compositions and methods for treating inflammasome related diseases or conditions
JP2021006543A (ja) 好酸球又はマスト細胞関連障害の治療
US20230340091A1 (en) Antibodies for the treatment of synucleinopathies and neuroinflammation
US20230238030A1 (en) Methods for modulating inflammasome activity and inflammation in the lung
US20090155204A1 (en) Methods for treating disorders involving monocytes
US20220153826A1 (en) Methods and compositions for treating virus-associated inflammation
US20220372159A1 (en) Treatment and Prevention of Ischemic Diseases And/Or Ischemic Tissue Damages
TW202033558A (zh) 化膿性汗腺炎治療中使用的抗cd40抗體
US20240124570A1 (en) Inflammasome antibody compositon and method for treating neurologic disorder
WO2024055015A1 (en) Inflammasome antibody compositon and method for treating neurologic disorder
NZ755639A (en) Method for modulating inflammasome activity and inflammation in the lung

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF MIAMI SCHOOL OF MEDICINE;REEL/FRAME:053701/0118

Effective date: 20200827

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH, MARYLAND

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:MIAMI, UNIVERSITY OF;REEL/FRAME:064987/0249

Effective date: 20200903